Eli Lilly (LLY): Foundayo Moves Closer to EU Authorization

Why it is trending

The European Medicines Agency’s human medicines committee has recommended marketing authorization for Lilly’s oral GLP-1 medicine Foundayo, also known as orforglipron. The positive opinion covers adult weight management and inadequately controlled type 2 diabetes, giving the tablet a potential path into two major treatment markets in the European Union.

This advances Lilly’s regulatory progress beyond its injectable obesity and diabetes portfolio. European Commission authorization is still pending. Commercial access and uptake would determine how much the opportunity contributes to future sales.

Sector

Health Care — pharmaceuticals, diabetes and obesity treatments.

Recent earnings

ATA Ultimate Swing Algorithm V2 Review

The small green daily dots show an upward daily bias, while the large green weekly diamonds show an upward weekly bias. Both timeframes are aligned, with the weekly signal carrying more weight in the overall assessment.

The separate weekly stage panel shows WS2 Up Trend ON. That stage supports the broader trend assessment, but the current dots and diamonds describe continuing bias rather than establishing a fresh BUY event. Comparing the faster daily view with the dominant weekly view helps keep decisions consistent instead of reacting to every short-term move. This is a framework for discipline, not a prediction of returns.

WE PREPARE FOR THE NEXT MOVE RATHER THAN PREDICT IT.

Sunday October 18, 2026